Photo by nci from unsplash
Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase… Click to show full abstract
Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.
Keywords:
lorlatinib alk;
lung cancer;
cancer;
alk rearranged;
rearranged lung
Journal Title: Cancer cell
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer cell
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!